250 related articles for article (PubMed ID: 35881325)
1. Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the USA.
Chen JV; Gahn JC; Nesheim J; Mudd PN
Pharmacoeconomics; 2022 Oct; 40(10):979-988. PubMed ID: 35881325
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States.
Chen JV; Klein TM; Nesheim J; Mudd PN
J Med Econ; 2022; 25(1):1092-1100. PubMed ID: 35993729
[TBL] [Abstract][Full Text] [Related]
3. Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.
Perk S; Wielage RC; Campbell NL; Klein TM; Perkins A; Posta LM; Yuran T; Klein RW; Ng DB
J Manag Care Spec Pharm; 2016 Sep; 22(9):1072-84. PubMed ID: 27579830
[TBL] [Abstract][Full Text] [Related]
4. Real-World Adherence to and Persistence with Vibegron in Patients with Overactive Bladder: A Retrospective Claims Analysis.
Chastek B; Carrera A; Landis C; Snyder D; Abedinzadeh L; Bancroft T; Nesheim J; Kennelly M; Staskin D
Adv Ther; 2024 May; 41(5):2086-2097. PubMed ID: 38520502
[TBL] [Abstract][Full Text] [Related]
5. Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial health-plan and Medicare Advantage perspectives.
Wielage RC; Perk S; Campbell NL; Klein TM; Posta LM; Yuran T; Klein RW; Ng DB
J Med Econ; 2016 Dec; 19(12):1135-1143. PubMed ID: 27326725
[TBL] [Abstract][Full Text] [Related]
6. Study design of a phase 4, real-world study (COMPOSUR) to evaluate vibegron in patients with overactive bladder.
Dmochowski RR; Rovner ES; Kennelly MJ; Newman DK; Abedinzadeh L; Snyder D; Thomas E; Haag-Molkenteller C; Rosenberg MT
BMC Urol; 2023 Apr; 23(1):64. PubMed ID: 37095473
[TBL] [Abstract][Full Text] [Related]
7. Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial.
Mitcheson HD; Samanta S; Muldowney K; Pinto CA; Rocha BA; Green S; Bennett N; Mudd PN; Frenkl TL
Eur Urol; 2019 Feb; 75(2):274-282. PubMed ID: 30661513
[TBL] [Abstract][Full Text] [Related]
8. The Budget Impact of Including Necitumumab on the Formulary for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer: U.S. Commercial Payer and Medicare Perspectives.
Bly CA; Molife C; Brown J; Tawney MK; Carter GC; Cinfio FN; Klein RW
J Manag Care Spec Pharm; 2018 Jun; 24(6):534-543. PubMed ID: 29799326
[TBL] [Abstract][Full Text] [Related]
9. Health Resource Utilization and Cost for Patients with Incontinent Overactive Bladder Treated with Anticholinergics.
Yehoshua A; Chancellor M; Vasavada S; Malone DC; Armstrong EP; Joshi M; Campbell K; Pulicharam R
J Manag Care Spec Pharm; 2016 Apr; 22(4):406-13. PubMed ID: 27023694
[TBL] [Abstract][Full Text] [Related]
10. Patient and Clinician Challenges with Anticholinergic Step Therapy in the Treatment of Overactive Bladder: A Narrative Review.
Dmochowski RR; Newman DK; Rovner ES; Zillioux J; Malik RD; Ackerman AL
Adv Ther; 2023 Nov; 40(11):4741-4757. PubMed ID: 37725308
[TBL] [Abstract][Full Text] [Related]
11. Vibegron, a Novel Potent and Selective β
Yoshida M; Takeda M; Gotoh M; Nagai S; Kurose T
Eur Urol; 2018 May; 73(5):783-790. PubMed ID: 29366513
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison.
Kennelly MJ; Rhodes T; Girman CJ; Thomas E; Shortino D; Mudd PN
Adv Ther; 2021 Nov; 38(11):5452-5464. PubMed ID: 34537953
[TBL] [Abstract][Full Text] [Related]
13. Evaluating vibegron for the treatment of overactive bladder.
Rechberger T; Wróbel A
Expert Opin Pharmacother; 2021 Jan; 22(1):9-17. PubMed ID: 32993398
[TBL] [Abstract][Full Text] [Related]
14. Vibegron: a β
Paton DM
Drugs Today (Barc); 2021 Aug; 57(8):507-517. PubMed ID: 34405208
[TBL] [Abstract][Full Text] [Related]
15. Vibegron for the treatment of overactive bladder: a comprehensive update.
Gleicher S; Sebesta EM; Reynolds WS; Dmochowski R
Expert Opin Pharmacother; 2022 Sep; 23(13):1479-1484. PubMed ID: 36124780
[TBL] [Abstract][Full Text] [Related]
16. Urodynamic evaluation of the efficacy of vibegron, a new β3-adrenergic receptor agonist, on lower urinary tract function in children and adolescents with overactive bladder.
Kitta T; Chiba H; Kon M; Higuchi M; Kusakabe N; Ouchi M; Togo M; Abe-Takahashi Y; Tsukiyama M; Shinohara N
J Pediatr Urol; 2022 Oct; 18(5):563-569. PubMed ID: 35965225
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of Vibegron in treating overactive bladder: A systematic review and pooled analysis of randomized controlled trials.
Shi H; Chen H; Zhang Y; Cui Y
Neurourol Urodyn; 2020 Jun; 39(5):1255-1263. PubMed ID: 32421908
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of real-world adherence and persistence patterns with vibegron, mirabegron, and anticholinergics in patients with overactive bladder: A retrospective claims study.
Chastek B; Carrera A; Landis C; Snyder D; Abedinzadeh L; Bancroft T; Nesheim J; Kennelly M; Staskin D
Neurourol Urodyn; 2024 May; ():. PubMed ID: 38720543
[TBL] [Abstract][Full Text] [Related]
19. Urodynamic effectiveness of a beta-3 adrenoreceptor agonist (vibegron) for a pediatric patient with anticholinergic-resistant neurogenic detrusor overactivity: a case report.
Kato T; Mizuno K; Nishio H; Yasui T; Hayashi Y
J Med Case Rep; 2021 Feb; 15(1):86. PubMed ID: 33602290
[TBL] [Abstract][Full Text] [Related]
20. Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study.
Szabo SM; Gooch K; Schermer C; Walker D; Lozano-Ortega G; Rogula B; Deighton A; Vonesh E; Campbell N
BMJ Open; 2019 May; 9(5):e026391. PubMed ID: 31061036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
